Aliskiren/amlodipine
| Combination of | |
|---|---|
| Aliskiren | Renin inhibitor |
| Amlodipine | Calcium channel blocker (dihydropyridine) |
| Clinical data | |
| Trade names | Tekamlo |
| AHFS/Drugs.com | Consumer Drug Information |
| License data | |
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
  (what is this?) (verify) | |
The drug combination aliskiren/amlodipine (INNs, trade name Tekamlo) is an antihypertensive. Clinical trials have shown it to be more effective than amlodipine on its own,[1] with a high dosing regime (aliskiren 300 mg/amlodipine 10 mg) being more effective than olmesartan/amlodipine with comparable tolerability.[2]
References
- ^ Pfeiffer, Dietrich; Rennie, Nicola; C. Papst, Cheraz; Zhang, Jack (2012). "Efficacy and Tolerability of Aliskiren/Amlodipine Single-Pill Combinations in Patients who did not Respond Fully to Amlodipine Monotherapy". Current Vascular Pharmacology. 10 (6): 773–780. doi:10.2174/157016112803520945. ISSN 1570-1611.
- ^ Axthelm, Christoph; Sieder, Christian; Meister, Franziska; Kaiser, Edelgard (2011). "Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg". Current Medical Research and Opinion. 28 (1): 69–78. doi:10.1185/03007995.2011.637914. ISSN 0300-7995.
External links
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |